CRISPR Quest

Thursday, February 24, 2022 at 1:00 p.m. ET / 10:00 a.m. PT

Last summer Intellia reported the first data showing that CRISPR could be used in the body to combat a disease – in this case, a rare nerve disorder. That early data was so eye-catching it was published in the New England Journal of Medicine. But what are the next steps? The company’s CEO joins STAT to lay them out and answer your questions.

• John Leonard, M.D., president and chief executive officer, Intellia Therapeutics
• Chris Coburn, chief innovation officer, Mass General Brigham (sponsor speaker)
• Matthew Herper, senior writer, medicine; editorial director of events, STAT (moderator)